Ribozyme-mediated cleavage of c-fos mRNA reduces gene expression of DNA synthesis enzymes and metallothionein - PubMed (original) (raw)

Ribozyme-mediated cleavage of c-fos mRNA reduces gene expression of DNA synthesis enzymes and metallothionein

K J Scanlon et al. Proc Natl Acad Sci U S A. 1991.

Abstract

The c-fos gene product Fos has been implicated in many cellular processes, including signal transduction, DNA synthesis, and resistance to antineoplastic agents. A fos ribozyme (catalytic RNA) was designed to evaluate the effects of suppressing Fos protein synthesis on expression of enzymes involved in DNA synthesis, DNA repair, and drug resistance. DNA encoding the fos ribozyme (fosRb) was cloned into the pMAMneo expression plasmid, and the resultant vector was transfected into A2780DDP cells resistant to the chemotherapeutic agent cisplatin. The parental drug-sensitive A2780S cells were transfected with the pMMV vector containing the c-fos gene. Morphological alterations were accompanied by significant changes in pharmacological sensitivity in both c-fos- and fosRb-transfected cells. pMAMneo fosRb transfectants revealed decreased c-fos gene expression, concomitant with reduced thymidylate (dTMP) synthase, DNA polymerase beta, topoisomerase I, and metallothionein IIA mRNAs. In contrast, c-myc expression was elevated after fos ribozyme action. Insertion of a mutant ribozyme, mainly capable of antisense activity, into A2780DDP cells resulted in smaller reductions in c-fos gene expression and in cisplatin resistance than the active ribozyme. These studies establish a role for c-fos in drug resistance and in mediating DNA synthesis and repair processes by modulating expression of genes such as dTMP synthase, DNA polymerase beta, and topoisomerase I. These studies also suggest the utility of ribozymes in the analysis of cellular gene expression.

PubMed Disclaimer

Similar articles

• [Circumventing drug resistance in human tumors by antisense ribozyme].
  Funato T. Funato T. Gan To Kagaku Ryoho. 1994 Feb;21(3):336-42. Gan To Kagaku Ryoho. 1994. PMID: 8109989 Japanese.
• The utility of an anti-fos ribozyme in reversing cisplatin resistance in human carcinomas.
  Funato T, Yoshida E, Jiao L, Tone T, Kashani-Sabet M, Scanlon KJ. Funato T, et al. Adv Enzyme Regul. 1992;32:195-209. doi: 10.1016/0065-2571(92)90017-t. Adv Enzyme Regul. 1992. PMID: 1496917
• Ribozyme-mediated reversal of the multidrug-resistant phenotype.
  Scanlon KJ, Ishida H, Kashani-Sabet M. Scanlon KJ, et al. Proc Natl Acad Sci U S A. 1994 Nov 8;91(23):11123-7. doi: 10.1073/pnas.91.23.11123. Proc Natl Acad Sci U S A. 1994. PMID: 7972021 Free PMC article.
• [Circumventing multidrug resistance in human cancer by anti-ribozyme].
  Funato T. Funato T. Nihon Rinsho. 1997 May;55(5):1116-21. Nihon Rinsho. 1997. PMID: 9155162 Review. Japanese.
• [Reversal of drug resistance in human cancer cells by anti-oncogenes].
  Funato T. Funato T. Gan To Kagaku Ryoho. 1997 Feb;24(4):395-400. Gan To Kagaku Ryoho. 1997. PMID: 9063474 Review. Japanese.

Cited by

• Ligand-directed cancer gene therapy to angiogenic vasculature.
  Driessen WHP, Ozawa MG, Arap W, Pasqualini R. Driessen WHP, et al. Adv Genet. 2009;67:103-121. doi: 10.1016/S0065-2660(09)67004-8. Adv Genet. 2009. PMID: 19914451 Free PMC article. Review.
• Expression of apoptosis-related oncoproteins and modulation of apoptosis by caffeine in human leukemic cells.
  Efferth T, Fabry U, Glatte P, Osieka R. Efferth T, et al. J Cancer Res Clin Oncol. 1995;121(11):648-56. doi: 10.1007/BF01218522. J Cancer Res Clin Oncol. 1995. PMID: 7593128
• Ribozyme mediated degradation of beta-amyloid peptide precursor mRNA in COS-7 cells.
  Denman RB, Smedman M, Ju W, Rubenstein R, Potempska A, Miller DL. Denman RB, et al. Nucleic Acids Res. 1994 Jun 25;22(12):2375-82. doi: 10.1093/nar/22.12.2375. Nucleic Acids Res. 1994. PMID: 8036167 Free PMC article.
• Design and specificity of hammerhead ribozymes against calretinin mRNA.
  Ellis J, Rogers J. Ellis J, et al. Nucleic Acids Res. 1993 Nov 11;21(22):5171-8. doi: 10.1093/nar/21.22.5171. Nucleic Acids Res. 1993. PMID: 8255773 Free PMC article.
• Are RAS mutations predictive markers of resistance to standard chemotherapy?
  Loriot Y, Mordant P, Deutsch E, Olaussen KA, Soria JC. Loriot Y, et al. Nat Rev Clin Oncol. 2009 Sep;6(9):528-34. doi: 10.1038/nrclinonc.2009.106. Epub 2009 Jul 14. Nat Rev Clin Oncol. 2009. PMID: 19597509 Review.

References

1. 1. Annu Rev Biochem. 1986;55:599-629 - PubMed
2. 1. Cell. 1987 Apr 24;49(2):211-20 - PubMed
3. 1. J Biol Chem. 1989 May 25;264(15):8992-9 - PubMed
4. 1. Science. 1988 Sep 30;241(4874):1813-5 - PubMed
5. 1. Nature. 1984 Oct 4-10;311(5985):433-8 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Europe PubMed Central
  • PubMed Central

• Other Literature Sources

  • The Lens - Patent Citations Database